{
    "title": "114_hr512",
    "content": "The Act titled \"Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015\" also known as the \"DISARM Act of 2015\" aims to encourage the development and use of DISARM antimicrobial drugs. The DISARM Act of 2015 amends the Social Security Act to provide additional payment for DISARM antimicrobial drugs under Medicare starting from October 1, 2015. The Secretary will recognize the costs of these drugs and provide additional payment for discharges involving DISARM. The DISARM Act of 2015 amends the Social Security Act to provide additional payment for DISARM antimicrobial drugs under Medicare starting from October 1, 2015. The subsection defines DISARM antimicrobial drugs as products approved by the FDA on or after January 1, 2015, intended to treat infections caused by qualifying pathogens. The DISARM Act of 2015 provides additional payment for DISARM antimicrobial drugs under Medicare. These drugs must meet specific criteria, including being intended to treat infections with unmet medical needs or high mortality rates. The DISARM Act of 2015 provides additional payment for DISARM antimicrobial drugs under Medicare. These drugs must meet specific criteria, including being intended to treat infections with unmet medical needs or high mortality rates. Manufacturers can request the Secretary to designate a drug as a DISARM antimicrobial drug before or after submitting an application under section 505(b) of the Act. The designated drug must be used in facilities that participate in the National Healthcare Safety Network of the CDC or a similar reporting program specified by the Secretary. The Secretary will determine if a drug is a DISARM antimicrobial drug within 60 days of the submission of the application. The designation of a drug as a DISARM antimicrobial drug cannot be withdrawn, except if the Secretary revokes it for specific reasons. The Secretary will publish a list of DISARM antimicrobial drugs in the Federal Register by October 1, 2016. Adjustments will be made to ensure payments under this subsection are not greater or less than those that would otherwise be made for a fiscal year. This relates to NTAP payments under the Social Security Act. The paragraph is amended to include criteria for new medical services and technologies that are not DISARM antimicrobial drugs. A study will be conducted to remove barriers to the development of DISARM antimicrobial drugs. A study will be conducted to identify barriers to developing DISARM antimicrobial drugs and provide recommendations to overcome them. The Comptroller General will submit a report to Congress within 1 year of the enactment of the Act."
}